In an intriguing turn of events amidst a multidistrict antitrust litigation, India-based pharmaceutical giant, Ranbaxy Laboratories Ltd., has entreated the intervention of a New Jersey federal court. The litigation pertains to the cholesterol drug, Lipitor.
According to a recent report, the company has petitioned for the postponement of an upcoming class certification hearing due to unexpected and grave circumstances that have befallen one of the case’s key legal counsels. The unidentified lawyer faces a stark predicament, as explained by Ranbaxy, finding himself “trapped in the war-torn regions of Israel with no foreseeable means of escape.”
Given the pivotal role of this counsel in the proceedings and the extreme nature of this situation, Ranbaxy’s request is noteworthy. It is yet to be seen whether the court will grant the sought-after delay and what implications it may have for the ongoing antitrust litigation about Lipitor. In-depth details related to this exceptional situation are not readily available but more information can be found at the original report.